Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01NR017018-01 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Nursing Research (NINR) | NIH |
Not provided
Not provided
Not provided
Not provided
Despite advances in dialysis, only 50% of dialysis patients are alive 3 years after the onset of end-stage renal disease (ESRD). Although withdrawal of dialysis precedes 1 in 4 deaths of patients with ESRD, withdrawal from dialysis and aggressive treatment is rarely discussed by patients and their surrogates with sufficient time to consider alternatives such as hospice or dying at home. Over the last decade, the researchers have developed and iteratively tested a patient and family-centered advance care planning intervention based on the Representational Approach to Patient Education called "Sharing Patient's Illness Representation to Increase Trust" (SPIRIT). SPIRIT is a 6-step, 2-session, face-to-face intervention to promote cognitive and emotional preparation for end-of-life decision making for patients with ESRD and their surrogates.
This study is a multicenter, clinic-level cluster randomized trial to evaluate the effectiveness of SPIRIT delivered by dialysis care providers as part of routine care in free-standing outpatient dialysis clinics compared to usual care plus delayed SPIRIT implementation. The researchers will recruit 400 dyads of patients at high risk of death in the next year and their surrogates from dialysis clinics in four states. Patients and surrogates will complete questionnaires at baseline and two weeks after the intervention. Surrogates will complete a post-bereavement assessment three months after the death of the patient.
End-stage renal disease (ESRD) currently affects nearly 662,000 people in the U.S. While dialysis is the treatment of choice for over 90% of patients with ESRD and is universally covered by Medicare regardless of patient age or means, the likelihood that dialysis can restore health or prolong life is limited; only 50% of dialysis patients are alive 3 years after the onset of ESRD. Thus many dialysis patients and their family members or surrogate decision-makers have to face difficult end-of-life decisions. Although advance care planning (ACP), in which patients and surrogate decision-makers discuss future health states and treatment options, is a central tenet of dialysis care, the vast majority of dialysis patients (>90%) report never engaging in ACP discussions with their care providers. The lack of effective ACP to prepare patients and their surrogates for end-of-life decision making with sufficient time before death has deleterious consequences at all levels of society. Consequences have been well documented: prolonged use of futile treatment at the end of life, which misuses the healthcare system, high levels of surrogate distress during decision making, which emanates from not having a clear understanding of the patient's wishes, and surrogates experiencing later sequelae of psychosocial morbidities, such as depression and family discord.
"Sharing Patient's Illness Representation to Increase Trust" (SPIRIT), a patient and family-centered ACP intervention based on the Representational Approach to Patient Education, was designed by the research team to establish a testable model of how end-of-life care discussions could occur between a dialysis patient and his/her chosen surrogate (usually a spouse or adult child). The discussions, which are facilitated by a trained care provider, are framed around addressing each individual's representations of (beliefs about) the illness and views of life-sustaining measures at the end of life. SPIRIT follows a six-step learning objective over two-sessions, which together take about 60 minutes. The care provider, who is value-neutral, guides the patient in examining his/her values related to end-of-life care, helps the surrogate understand the patient's illness progression, and prepares the surrogate for his/her role as a surrogate in a highly emotionally charged medical setting. Over the last decade, SPIRIT has been tested to establish feasibility, patient-surrogate acceptability, and efficacy. In these explanatory trials carried out in dialysis clinics, SPIRIT was delivered by trained research nurses. Patients and surrogates in SPIRIT showed significant improvement in preparedness for end-of-life decision making, including the extent to which: a) the patient and surrogate agreed on end-of-life care goals, b) the patient had reduced conflict about the benefits and burdens of life-sustaining treatments, and c) the surrogate had increased confidence about the role of surrogate. Key to establishing the utility of this approach for broader generalizability, surrogates who received SPIRIT reported significantly improved post-bereavement psychological outcomes after the patient's death compared to those who did not. The logical, critical next step is to ask: Will SPIRIT be effective as part of routine care in real-world clinical settings with less control? To address this very issue, the researchers will conduct a real-world effectiveness-implementation study, an essential step prior to widespread implementation of SPIRIT.
This study is a multicenter, clinic-level cluster randomized trial to evaluate the effectiveness of SPIRIT delivered by dialysis care providers as part of routine care in free-standing outpatient dialysis clinics compared to usual care plus delayed SPIRIT implementation. Simultaneously, the researchers will evaluate the implementation of SPIRIT, including sustainability. This study will use a Type I effectiveness-implementation hybrid approach that combines testing intervention effectiveness and gathering information about implementation of an efficacious intervention in a real world setting. To maximize data on the implementation process and sustainability, the researchers chose a delayed intervention design in which clinics are randomized either to implement SPIRIT immediately after randomization (i.e., initial implementation) or to maintain usual care for a comparison condition and then implement the intervention in control clinics following conclusion of this clinical trial (i.e., delayed implementation). The intent of the delayed implementation group was provide descriptive data for translation of the intervention into clinical practice (versus data collected on dyad participants in this current study), however, this portion of the study could not be performed due to the coronavirus disease 2019 (COVID-19) pandemic.
The short-term goal is to generate sufficient evidence to accelerate the integration of SPIRIT into dialysis practice and policy. This study will recruit 400 dyads of patients at high risk of death in the next year and their surrogates (a total of 800 individuals) from dialysis clinics in four states. The dialysis clinics will be randomized to implement SPIRIT or to maintain usual care to serve as a control to the intervention. Participants will complete a follow-up assessment two weeks after the the study intervention. They will then be observed for 9 months (or until the death of the patient) with an optional extension of the observational period for an additional 12 months, for up to 21 months of observation. Individual patient participation will end after the observation period (9 or 21 months) or death, whichever occurs first; surrogate participation will end after the observation period (9 or 21 months) or at the completion of the post-bereavement surveys which are administered 3-months after the death of the patient (up to 24 months).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SPIRIT Clinic | Experimental | Patients at clinics that have been randomized to the SPIRIT arm will be given the option to participate in the intervention. SPIRIT is a two-session, 60-minute, structured psychoeducational intervention, targeting both patient and surrogate. Using a provider manual, the care provider follows six steps: 1) assessing illness presentation, 2) identifying gaps and concerns, 3) creating conditions for conceptual change, 4) introducing replacement information, 5) summarizing, and 6) setting goals and planning. |
|
| Comparison Condition Clinic | Active Comparator | Patients at clinics that have been randomized to the control arm will be given the option to participate as a study control. The control clinics will have delayed implementation of the SPIRIT intervention. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SPIRIT | Behavioral | SPIRIT is a two-session, structured psychoeducational intervention assisting patients clarify their end-of-life preferences and helping surrogates understand the patient's wishes and prepare for the surrogate role. During the first session (about 45 minutes) individualized information is provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the care provider will assist the patient to examine his/her values about life-sustaining treatment. The surrogate will receive help preparing for end-of-life decision-making and the emotional burden of decision-making. A Goals-of-Care document will be completed to indicate the patient's preferences. Two weeks later, the second session (about 15 minutes) addresses remaining or new concerns. The patient's Goals-of-Care document will be reviewed. The patient's end-of-life preferences and surrogate's name and relationship to the patient will be documented in the medical record. |
| Measure | Description | Time Frame |
|---|---|---|
| Dyad Congruence on Goals-of-Care Tool | The Goals-of-Care Tool which includes two scenarios describing medical conditions commonly occurring in end-stage renal disease (ESRD) patients. Possible responses to the scenarios are: "The goals of care should focus on delaying my death, and thus I want to continue life-sustaining treatment", "The goals of care should focus on my comfort and peace, and thus I do not want life-sustaining treatment, including dialysis", and "I am not sure". Patients and surrogates complete this tool independently and their responses are compared to determine dyad congruence. A dyad is assigned with "1" if each member of the dyad chose the same response (either comfort care only or continue aggressive care) in both scenarios. In all other cases, the dyad is assigned with "0", which includes: 1) the patient and surrogate responses are the same in one of the two scenarios, 2) the patient and surrogate responses differ in both scenarios, and 3) the patient and surrogate responses are both "I am not sure". | Baseline, Week 2 |
| Patient's Decisional Conflict Scale (DCS) Score | Patient decisional conflict is measured using the 13-item Decisional Conflict Scale (DCS), a validated measure in the context of end-of-life decision making. Participants indicate their level of agreement with statements about their plans for their future medical care by selecting (1) Strongly Agree, (2) Agree, (3) Neither Agree nor Disagree, (4) Disagree, or (5) Strongly Disagree. The total score ranges from 13 to 65 with higher scores indicating greater difficulty in weighing benefits and burdens of life-sustaining treatments and decision making. | Baseline, Week 2 |
| Surrogate's Decision Making Confidence (DMC) Scale Score | Surrogate decision-making confidence is measured using the 5-item Decision Making Confidence (DMC) scale. Surrogates indicate how confident they are about making medical decisions if the patient becomes unable to make their own decisions by their level of agreement with statements along a scale of (0) "Not confident at all" to (4) "Very confident". Total scores range from 0 to 20, with higher scores indicating greater confidence. | Baseline, Week 2 |
| Measure | Description | Time Frame |
|---|---|---|
| End-of-life Treatment Intensity Among Participants With Medicare | The use of intensive procedures during end-of-life treatment is identified through the United States Renal Data System (USRDS). Among participants having Medicare, admission to hospice, withdrawal of dialysis, and institutional death were documented. | Upon patient death (up to 21 months) |
Not provided
Inclusion Criteria for Patients:
Exclusion Criteria for Patients:
Inclusion Criteria for Surrogates:
Exclusion Criteria for Surrogates:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mi-Kyung Song, PhD, RN | Emory University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Emory Dialysis at Northside | Atlanta | Georgia | 30318 | United States | ||
| Emory Dialysis at Greenbriar |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28993286 | Background | Song MK, Unruh ML, Manatunga A, Plantinga LC, Lea J, Jhamb M, Kshirsagar AV, Ward SE. SPIRIT trial: A phase III pragmatic trial of an advance care planning intervention in ESRD. Contemp Clin Trials. 2018 Jan;64:188-194. doi: 10.1016/j.cct.2017.10.005. Epub 2017 Oct 6. | |
| 38289604 | Derived | Song MK, Manatunga A, Plantinga L, Metzger M, Kshirsagar AV, Lea J, Abdel-Rahman EM, Jhamb M, Wu E, Englert J, Ward SE. Effectiveness of an Advance Care Planning Intervention in Adults Receiving Dialysis and Their Families: A Cluster Randomized Clinical Trial. JAMA Netw Open. 2024 Jan 2;7(1):e2351511. doi: 10.1001/jamanetworkopen.2023.51511. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
42 clinics were enrolled with 23 randomized to the SPIRIT and 19 randomized to usual care. One SPIRIT clinic and 2 control clinics were excluded prior to study initiation. There were 557 eligible patients in SPIRIT clinics and 264 dyads consented to participate; of these, 33 dyads withdrew or became ineligible prior to the baseline visit. In control clinics there were 293 eligible patients and 210 dyads consented to participate; 15 dyads withdrew or became ineligible prior to the baseline visit.
Participants were recruited from multiple dialysis centers in Georgia, New Mexico, North Carolina, Pennsylvania, and Virginia, USA. Participant enrollment began on February 15, 2018, and follow-up assessments for the primary outcome measures at Week 2 were completed on March 24, 2022. Data collection for secondary outcome measures with surrogates three months after the patient's death was completed July 29, 2022.
| ID | Title | Description |
|---|---|---|
| FG000 | SPIRIT Clinic | Dialysis clinics randomized to deliver the SPIRIT intervention. SPIRIT is a two-session, 60-minute, structured psychoeducational intervention, targeting both patient and surrogate. Using a provider manual, the care provider follows six steps: 1) assessing illness presentation, 2) identifying gaps and concerns, 3) creating conditions for conceptual change, 4) introducing replacement information, 5) summarizing, and 6) setting goals and planning. Patients receiving care at SPIRIT clinics were given the option to participate in this study with their surrogate decision-makers. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Apr 8, 2021 |
Not provided
Dialysis clinics are randomized to provide the intervention or usual care. Patients of those clinics will be given the opportunity to participate in the study and will receive the intervention or usual care based on which clinic they attend.
Not provided
Not provided
Not provided
Not provided
|
|
| Comparison Condition | Behavioral | As required by Centers for Medicare and Medicaid Services (CMS), written information on advance directives (ADs) is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an AD. This typically takes about 10 minutes. |
|
|
| Composite Outcome of Dyad Congruence and Surrogate DMC Score | The composite outcome combines dyad congruence on Goals-of-Care scenarios and surrogate DMC scores. If the dyad congruence is 1 and the surrogate's DMC >=3, then the composite outcome value for the dyad is "1". In all other cases, the dyad's composite outcome value is "0". | Baseline, Week 2 |
| End-of-life Treatment Intensity Among Participants With Medicare as the Primary Payer | The use of intensive procedures during end-of-life treatment is identified through the United States Renal Data System (USRDS). Among participants having Medicare as the primary payer, admission to the hospital, intensive care unit, or a skilled nursing facility was documented, as well as intensive procedures of cardiopulmonary resuscitation (CPR), intubation, mechanical ventilation, and feeding (gastronomy or jejunal) tube insertion. | Upon patient death (up to 21 months) |
| Surrogate's Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score | Surrogate post-bereavement anxiety symptoms were measured with the Hospital Anxiety and Depression Scale (HADS) Anxiety subscale. Surrogates indicate their level of agreement with statements by selecting responses rated from 0 (the problem in the statement is not an issue) to 3 (the problem in the statement is a very big issue). Scores for the anxiety subscale range from 0 to 21 with higher scores indicating greater symptom severity. A score of 0-7 indicates "normal", 8-10 indicates "borderline abnormal", and 11-21 indicates "abnormal" levels of anxiety. | Baseline, 3 months after patient death (up to 24 months) |
| Surrogate's Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score | Surrogate post-bereavement symptoms of depression were measured with the Hospital Anxiety and Depression Scale (HADS) Depression subscale. Surrogates indicate their level of agreement with statements by selecting responses rated from 0 (the problem in the statement is not an issue) to 3 (the problem in the statement is a very big issue). Total scores of the depression subscale range from 0 to 21 with higher scores indicating greater symptom severity. A score of 0-7 indicates "normal", 8-10 indicates "borderline abnormal", and 11-21 indicates "abnormal" levels of depression. | Baseline, 3 months after patient death (up to 24 months) |
| Surrogate's Post-Traumatic Symptoms Scale-10 (PTSS-10) Score | Surrogate post-bereavement traumatic distress was measured with the Post-Traumatic Symptoms Scale-10 (PTSS-10). Surrogates indicate how often they have experienced symptoms of post-traumatic stress by responding to 10 symptoms on a scale of 1 to 7 where 1 = "never" and 7 = "always". Total scale scores range from 10 to 70 and higher scores indicate more intense symptoms. | Baseline, 3 months after patient death (up to 24 months) |
| Atlanta |
| Georgia |
| 30331 |
| United States |
| Emory Dialysis at Candler | Decatur | Georgia | 30034 | United States |
| Emory Dialysis Center | North Decatur | Georgia | 30033 | United States |
| Dialysis Clinic, Inc - Acoma Canoncito Laguna | Acoma Pueblo | New Mexico | 87034 | United States |
| Dialysis Clinic, Inc - Albuquerque | Albuquerque | New Mexico | 87102 | United States |
| Dialysis Clinic, Inc - Albuquerque South | Albuquerque | New Mexico | 87105 | United States |
| Dialysis Clinic, Inc - Albuquerque East | Albuquerque | New Mexico | 87110 | United States |
| Dialysis Clinic, Inc - Carlsbad | Carlsbad | New Mexico | 88220 | United States |
| Dialysis Clinic, Inc - Cuba | Cuba | New Mexico | 87013 | United States |
| Dialysis Clinic, Inc - Grants | Grants | New Mexico | 87020 | United States |
| Dialysis Clinic, Inc - Raton | Raton | New Mexico | 87740 | United States |
| Dialysis Clinic, Inc - Rio Rancho | Rio Rancho | New Mexico | 87124 | United States |
| Dialysis Clinic, Inc - Santo Domingo | Santo Domingo Pueblo | New Mexico | 87052 | United States |
| Dialysis Clinic, Inc - Silver City | Silver City | New Mexico | 88061 | United States |
| Dialysis Clinic, Inc - Taos | Taos | New Mexico | 87571 | United States |
| Carolina Dialysis - Carrboro | Carrboro | North Carolina | 27510 | United States |
| Carolina Dialysis - Mebane | Mebane | North Carolina | 27302 | United States |
| Carolina Dialysis - Pittsboro | Pittsboro | North Carolina | 27312 | United States |
| Fresenius Kidney Care - Raleigh | Raleigh | North Carolina | 27610 | United States |
| Carolina Dialysis-Sanford Lee County | Sanford | North Carolina | 27332 | United States |
| Carolina Dialysis-Sanford Main | Sanford | North Carolina | 27332 | United States |
| Carolina Dialysis - Siler City | Siler City | North Carolina | 27344 | United States |
| Dialysis Clinic, Inc - Harmar Village | Cheswick | Pennsylvania | 15024 | United States |
| Dialysis Clinic, Inc - Monroeville/Five Points | Monroeville | Pennsylvania | 15146 | United States |
| Dialysis Clinic, Inc - North Versailles | North Versailles | Pennsylvania | 15137 | United States |
| Dialysis Clinic, Inc - Oakland | Pittsburgh | Pennsylvania | 15213 | United States |
| Dialysis Clinic, Inc - Banksville | Pittsburgh | Pennsylvania | 15216 | United States |
| Dialysis Clinic, Inc - Wilkinsburg | Pittsburgh | Pennsylvania | 15221 | United States |
| Dialysis Clinic, Inc - North Hills | Pittsburgh | Pennsylvania | 15237 | United States |
| UVA Dialysis Altavista Clinic | Altavista | Virginia | 24517 | United States |
| UVA Dialysis Amherst Clinic | Amherst | Virginia | 24521 | United States |
| Kidney Center Outpatient Dialysis Clinic | Charlottesville | Virginia | 22903 | United States |
| UVA Dialysis Clinic Farmville | Farmville | Virginia | 23901 | United States |
| UVA Augusta Dialysis | Fishersville | Virginia | 22939 | United States |
| UVA Dialysis Zion Crossroads | Gordonsville | Virginia | 22942 | United States |
| UVA Dialysis Lynchburg | Lynchburg | Virginia | 24501 | United States |
| UVA Dialysis Orange Clinic | Orange | Virginia | 22960 | United States |
| UVA Dialysis Clinic Staunton | Staunton | Virginia | 24401 | United States |
| FG001 | Comparison Condition Clinic | Dialysis clinics randomized to the comparison condition control arm. The comparison condition is the usual care provided. As required by the Centers for Medicare and Medicaid Services (CMS), written information on advance directives (ADs) is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an AD. This typically takes about 10 minutes. Patients receiving care at the comparison condition clinics were given the option to participate in this study with their surrogate decision-makers. |
| Patients beginning the study |
|
| Surrogates beginning the study |
|
| Patients completing the Week 2 assessment |
|
| Surrogates completing the Week 2 assessment |
|
| Surrogates eligible for post-bereavement visit |
|
| Surrogates completing post-bereavement visit |
|
| COMPLETED | Completed Week 2 visit |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | SPIRIT Clinic - Patients | Patients receiving care at clinics randomized to the SPIRIT intervention |
| BG001 | SPIRIT Clinic - Surrogates | Surrogates of patients receiving care at clinics randomized to the SPIRIT intervention |
| BG002 | Comparison Condition Clinic - Patients | Patients receiving care at clinics randomized to the control condition |
| BG003 | Comparison Condition Clinic - Surrogates | Surrogates of patients receiving care at clinics randomized to the control condition |
| BG004 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Dyad Congruence on Goals-of-Care Tool | The Goals-of-Care Tool which includes two scenarios describing medical conditions commonly occurring in end-stage renal disease (ESRD) patients. Possible responses to the scenarios are: "The goals of care should focus on delaying my death, and thus I want to continue life-sustaining treatment", "The goals of care should focus on my comfort and peace, and thus I do not want life-sustaining treatment, including dialysis", and "I am not sure". Patients and surrogates complete this tool independently and their responses are compared to determine dyad congruence. A dyad is assigned with "1" if each member of the dyad chose the same response (either comfort care only or continue aggressive care) in both scenarios. In all other cases, the dyad is assigned with "0", which includes: 1) the patient and surrogate responses are the same in one of the two scenarios, 2) the patient and surrogate responses differ in both scenarios, and 3) the patient and surrogate responses are both "I am not sure". | The number of participants analyzed reflects the number of persons with ESRD and surrogate dyads (two persons per dyad). This analysis includes dyads who both completed the assessment at the indicated study visit. | Posted | Number | dyads | Baseline, Week 2 |
|
|
| |||||||||||||||||||||||||||||
| Primary | Patient's Decisional Conflict Scale (DCS) Score | Patient decisional conflict is measured using the 13-item Decisional Conflict Scale (DCS), a validated measure in the context of end-of-life decision making. Participants indicate their level of agreement with statements about their plans for their future medical care by selecting (1) Strongly Agree, (2) Agree, (3) Neither Agree nor Disagree, (4) Disagree, or (5) Strongly Disagree. The total score ranges from 13 to 65 with higher scores indicating greater difficulty in weighing benefits and burdens of life-sustaining treatments and decision making. | This analysis includes patient participants who completed the DCS. One participant in the comparison condition study arm did not answer all items on the scale at the baseline visit and thus their total score could not be computed. | Posted | Mean | Standard Deviation | score on a scale | Baseline, Week 2 |
|
| |||||||||||||||||||||||||||||
| Primary | Surrogate's Decision Making Confidence (DMC) Scale Score | Surrogate decision-making confidence is measured using the 5-item Decision Making Confidence (DMC) scale. Surrogates indicate how confident they are about making medical decisions if the patient becomes unable to make their own decisions by their level of agreement with statements along a scale of (0) "Not confident at all" to (4) "Very confident". Total scores range from 0 to 20, with higher scores indicating greater confidence. | This analysis includes participants completing the indicated study visit. | Posted | Mean | Standard Deviation | Score on a scale | Baseline, Week 2 |
|
| |||||||||||||||||||||||||||||
| Primary | Composite Outcome of Dyad Congruence and Surrogate DMC Score | The composite outcome combines dyad congruence on Goals-of-Care scenarios and surrogate DMC scores. If the dyad congruence is 1 and the surrogate's DMC >=3, then the composite outcome value for the dyad is "1". In all other cases, the dyad's composite outcome value is "0". | The number of participants analyzed reflects the number of persons with ESRD and surrogate dyads (two persons per dyad). This analysis includes dyads who both completed the assessments at the indicated study visit. | Posted | Number | dyads | Baseline, Week 2 |
|
| ||||||||||||||||||||||||||||||
| Secondary | End-of-life Treatment Intensity Among Participants With Medicare | The use of intensive procedures during end-of-life treatment is identified through the United States Renal Data System (USRDS). Among participants having Medicare, admission to hospice, withdrawal of dialysis, and institutional death were documented. | Among participants who died, 53 in the SPIRIT arm and 35 in the usual care arm had consented to the USRDS data match. Of those, 52 in the SPIRIT arm and 34 in the usual care arm were successfully linked with USRDS. In the SPIRIT arm, 51 participants had Medicare and 32 participants in the usual care arm had Medicare. | Posted | Count of Participants | Participants | Upon patient death (up to 21 months) |
|
| ||||||||||||||||||||||||||||||
| Secondary | End-of-life Treatment Intensity Among Participants With Medicare as the Primary Payer | The use of intensive procedures during end-of-life treatment is identified through the United States Renal Data System (USRDS). Among participants having Medicare as the primary payer, admission to the hospital, intensive care unit, or a skilled nursing facility was documented, as well as intensive procedures of cardiopulmonary resuscitation (CPR), intubation, mechanical ventilation, and feeding (gastronomy or jejunal) tube insertion. | Among participants who died, 53 in the SPIRIT arm and 35 in the usual care arm had consented to the USRDS data match. Of those, 52 in the SPIRIT arm and 34 in the usual care arm were successfully linked with USRDS. In the SPIRIT arm, 51 participants had Medicare and 32 participants in the usual care arm had Medicare. Medicare was the primary payer for 30 in the SPIRIT arm and 20 in the usual care arm. | Posted | Count of Participants | Participants | Upon patient death (up to 21 months) |
| |||||||||||||||||||||||||||||||
| Secondary | Surrogate's Hospital Anxiety and Depression Scale (HADS) Anxiety Subscale Score | Surrogate post-bereavement anxiety symptoms were measured with the Hospital Anxiety and Depression Scale (HADS) Anxiety subscale. Surrogates indicate their level of agreement with statements by selecting responses rated from 0 (the problem in the statement is not an issue) to 3 (the problem in the statement is a very big issue). Scores for the anxiety subscale range from 0 to 21 with higher scores indicating greater symptom severity. A score of 0-7 indicates "normal", 8-10 indicates "borderline abnormal", and 11-21 indicates "abnormal" levels of anxiety. | This analysis includes surrogates from dyads where the patient died during the follow-up period. Per the intent to treat analysis, surrogates of 89 deceased patients were to be analyzed, and baseline values are presented for these participants. Twelve did not complete the post-bereavement survey due to being lost to follow-up or not consenting to participate in the extended follow-up. Baseline and post-bereavement scores are presented for the 77 who completed the post-bereavement assessment. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 3 months after patient death (up to 24 months) |
| ||||||||||||||||||||||||||||||
| Secondary | Surrogate's Hospital Anxiety and Depression Scale (HADS) Depression Subscale Score | Surrogate post-bereavement symptoms of depression were measured with the Hospital Anxiety and Depression Scale (HADS) Depression subscale. Surrogates indicate their level of agreement with statements by selecting responses rated from 0 (the problem in the statement is not an issue) to 3 (the problem in the statement is a very big issue). Total scores of the depression subscale range from 0 to 21 with higher scores indicating greater symptom severity. A score of 0-7 indicates "normal", 8-10 indicates "borderline abnormal", and 11-21 indicates "abnormal" levels of depression. | This analysis includes surrogates from dyads where the patient died during the follow-up period. Per the intent to treat analysis, surrogates of 89 deceased patients were to be analyzed, and baseline values are presented for these participants. Twelve did not complete the post-bereavement survey due to being lost to follow-up or not consenting to participate in the extended follow-up. Baseline and post-bereavement scores are presented for the 77 who completed the post-bereavement assessment. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 3 months after patient death (up to 24 months) |
| ||||||||||||||||||||||||||||||
| Secondary | Surrogate's Post-Traumatic Symptoms Scale-10 (PTSS-10) Score | Surrogate post-bereavement traumatic distress was measured with the Post-Traumatic Symptoms Scale-10 (PTSS-10). Surrogates indicate how often they have experienced symptoms of post-traumatic stress by responding to 10 symptoms on a scale of 1 to 7 where 1 = "never" and 7 = "always". Total scale scores range from 10 to 70 and higher scores indicate more intense symptoms. | This analysis includes surrogates from dyads where the patient died during the follow-up period. Per the intent to treat analysis, surrogates of 89 deceased patients were to be analyzed, and baseline values are presented for these participants. Twelve did not complete the post-bereavement survey due to being lost to follow-up or not consenting to participate in the extended follow-up. Baseline and post-bereavement scores are presented for the 77 who completed the post-bereavement assessment. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 3 months after patient death (up to 24 months) |
|
Adverse events were documented during the intervention session (Day 1). Dyads remained in the study to be followed for patient deaths for 9 months and after that they could opt to be followed for an additional 12 months, for up to 21 months in total. When a patient died the surrogate was asked to complete a post-bereavement assessment 3 months after the patient death, and then their study participation was considered complete (up to 24 months).
Only adverse events related to the intervention, such as emotional distress, were documented during the intervention session. Patient deaths are reported in the mortality table, however, due to the population being examined and the nature of this study, deaths among patients with ESRD are not considered to be adverse events of the study. Patient deaths were collected to assess post-bereavement outcomes among surrogates.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | SPIRIT Clinic - Patients | Patients receiving care at clinics randomized to the SPIRIT intervention | 54 | 231 | 0 | 231 | 0 | 231 |
| EG001 | SPIRIT Clinic - Surrogates | Surrogates of patients receiving care at clinics randomized to the SPIRIT intervention | 1 | 231 | 0 | 231 | 0 | 231 |
| EG002 | Comparison Condition Clinic - Patients | Patients receiving care at clinics randomized to the control condition | 35 | 195 | 0 | 195 | 0 | 195 |
| EG003 | Comparison Condition Clinic - Surrogates | Surrogates of patients receiving care at clinics randomized to the control condition | 0 | 195 | 0 | 195 | 0 | 195 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Mi-Kyung Song, PhD, RN | Emory University | 404-727-3134 | mi-kyung.song@emory.edu |
| Mar 13, 2023 |
| Prot_SAP_002.pdf |
| ICF | No | No | Yes | Informed Consent Form | Jul 7, 2020 | May 9, 2022 | ICF_001.pdf |
| ID | Term |
|---|---|
| D007676 | Kidney Failure, Chronic |
| ID | Term |
|---|---|
| D051436 | Renal Insufficiency, Chronic |
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C013089 | ligroin |
Not provided
Not provided
Not provided
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Number of Incongruent Dyads at Baseline (assigned value = 0) |
|
|
| Number of Congruent Dyads at 2 Weeks Post-Intervention (assigned value = 1) |
|
|
| Number of Incongruent Dyads at 2 Weeks Post-Intervention (assigned value = 0) |
|
|
| Participants |
|
|
|
|
|
| Units | Counts |
|---|
| Participants |
|
|
|
|
Surrogates of patients receiving care at clinics randomized to the control condition
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Unknown |
|
| Unknown |
|